2 research outputs found
Experimental study of the efficacy of combined use of cancer vaccine and interferon
Aim: To study in in vivo model the efficacy of combined scheme of administration of cancer vaccine (CV) and interferon (IFN). Materials and Methods: Lewis lung carcinoma (LLC) was transplanted to male C57Bl mice. For treatment, CV prepared from LLC cells with the use of cytotoxic lectins of B. subtilis B-7025, and preparation of murine IFN-alpha were used. Therapeutic effect was evaluated by measurement of tumor volume and analysis of average life span (ALS) of treated animals. Immunologic study included determination of antitumor cytotoxicity of T-lymphocytes (CTL) and natural killer (NK) cells by radiometric method, functional activity of peritoneal macrophages (MP) β by colorimetric test with nitroazole blue, and evaluation of titers of tumor necrosis factor (TNF) and interleukins-1 and -2 (IL-1, 2). Results: It has been shown that the use of IFN preparation significantly elevated efficacy of vaccine therapy of solid form of LLC: duration of latent period of tumor growth elevated by 25%, ALS β by 28%, index of tumor growth inhibition β by 35β40%. Upon combined use of CV and IFN, significant activation of the cells β effectors of nonspecific immune defense (MP), and specific one (CTL) was observed. Conclusion: The obtained results evidence on perspectiveness of the development of combined schemes of administration of CV and IFN for elevation of the efficacy of vaccine therapy.Π¦Π΅Π»Ρ: ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ Π² ΡΠΊΡΠΏΠ΅ΡΠΈΠΌΠ΅Π½ΡΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΡ
Π΅ΠΌΡ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ Π²Π°ΠΊΡΠΈΠ½Ρ (ΠΠ)
ΠΈ ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠΎΠ½Π° (ΠΠ€Π). ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ Π»Π΅Π³ΠΊΠΎΠ³ΠΎ ΠΡΡΠΈΡ (ΠΠΠ) ΡΡΠ°Π½ΡΠΏΠ»Π°Π½ΡΠΈΡΠΎΠ²Π°Π»ΠΈ ΠΌΡΡΠ°ΠΌ-ΡΠ°ΠΌΡΠ°ΠΌ C57Bl.
ΠΠ»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΠ, ΠΏΡΠΈΠ³ΠΎΡΠΎΠ²Π»Π΅Π½Π½ΡΡ ΠΈΠ· ΠΊΠ»Π΅ΡΠΎΠΊ ΠΠΠ Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π»Π΅ΠΊΡΠΈΠ½ΠΎΠ² B. subtilis B-7025,
ΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΠΌΡΡΠΈΠ½ΠΎΠ³ΠΎ ΠΠ€Π. Π’Π΅ΡΠ°ΠΏΠ΅Π²ΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΡΡΠ΅ΠΊΡ ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΏΡΡΠ΅ΠΌ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΡ ΠΎΠ±ΡΠ΅ΠΌΠ° ΡΠΎΠ»ΠΈΠ΄Π½ΠΎΠΉ ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ ΠΈ Π°Π½Π°Π»ΠΈΠ·Π° ΡΡΠ΅Π΄Π½Π΅ΠΉ
ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΆΠΈΠ·Π½ΠΈ ΠΎΠΏΡΡΠ½ΡΡ
ΠΆΠΈΠ²ΠΎΡΠ½ΡΡ
. ΠΠΌΠΌΡΠ½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ°Π»ΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠΉ
ΡΠΈΡΠΎΡΠΎΠΊΡΠΈΡΠ½ΠΎΡΡΠΈ Π’-Π»ΠΈΠΌΡΠΎΡΠΈΡΠΎΠ² (Π¦Π’Π) ΠΈ ΠΏΡΠΈΡΠΎΠ΄Π½ΡΡ
ΠΊΠΈΠ»Π»Π΅ΡΠ½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ (ΠΠΠ) ΡΠ°Π΄ΠΈΠΎΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ; ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠΉ
Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΠ΅ΡΠΈΡΠΎΠ½Π΅Π°Π»ΡΠ½ΡΡ
ΠΌΠ°ΠΊΡΠΎΡΠ°Π³ΠΎΠ² (ΠΡ) Π² ΠΊΠΎΠ»ΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠΌ ΠΠ‘Π’-ΡΠ΅ΡΡΠ΅; ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠΈΡΡΠΎΠ² ΡΠ°ΠΊΡΠΎΡΠ° Π½Π΅ΠΊΡΠΎΠ·Π°
ΠΎΠΏΡΡ
ΠΎΠ»ΠΈ (Π€ΠΠ), ΠΈΠ½ΡΠ΅ΡΠ»Π΅ΠΉΠΊΠΈΠ½ΠΎΠ²-1 ΠΈ -2. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΏΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° ΠΠ€Π ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ
ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΡΠΎΠ»ΠΈΠ΄Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΠΌΠΎΠ΄Π΅Π»ΡΠ½ΠΎΠΉ ΠΠΠ: Π½Π° 25% ΠΏΠΎΠ²ΡΡΠ°Π΅ΡΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ Π»Π°ΡΠ΅Π½ΡΠ½ΠΎΠ³ΠΎ
ΠΏΠ΅ΡΠΈΠΎΠ΄Π°, Π½Π° 28% β ΡΡΠ΅Π΄Π½ΡΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΠΆΠΈΠ·Π½ΠΈ ΠΌΡΡΠ΅ΠΉ, Π½Π° 35β40% β ΠΈΠ½Π΄Π΅ΠΊΡ ΡΠΎΡΠΌΠΎΠΆΠ΅Π½ΠΈΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠΎΡΡΠ°. ΠΡΠΈ
ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΌ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠΈ ΠΠ ΠΈ ΠΠ€Π ΠΎΡΠΌΠ΅ΡΠ°ΡΡ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ Π°ΠΊΡΠΈΠ²Π°ΡΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ-ΡΡΡΠ΅ΠΊΡΠΎΡΠΎΠ² ΠΊΠ°ΠΊ Π½Π΅ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ
(ΠΡ), ΡΠ°ΠΊ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠΉ (Π¦Π’Π) ΠΈΠΌΠΌΡΠ½Π½ΠΎΠΉ Π·Π°ΡΠΈΡΡ. ΠΡΠ²ΠΎΠ΄Ρ: ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΡ ΡΠ²ΠΈΠ΄Π΅ΡΠ΅Π»ΡΡΡΠ²ΡΡΡ ΠΎ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ
ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ ΠΊΠΎΠΌΠ±ΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΡΡ
Π΅ΠΌ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΠ Ρ ΠΠ€Π, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΡ
ΠΏΠΎΠ²ΡΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΠΈ
Effect of anticancer drugs on production of transforming growth factor and expression of P53 and BCL-2 proteins by MCF-7 and T47D cell lines of human breast carcinoma
Aim: To compare the capability of methotrexate, cisplatin, doxorubicine and vincristine to induce production of the transforming growth factor b1 (TGF- b1) in two cell lines β MCF-7 and T47D β of human breast carcinoma, as well as to study sensitivity of these cells to TGF- b1 and mentioned anticancer drugs. Materials and Methods: ELISA for detection of TGF- b content in conditioned culture media and Western-blot analysis of the proapoptotic p53 and antiapoptotic Bcl-2 proteins were applied. Results: t47d cells showing higher resistance to growth inhibiting effect of TGF- b1 were also refractory to cisplatin. There was no difference between MCF-7 and T47D cells in their sensitivity to methotrexate and doxorubicine, although T47D cells were more sensitive to vincristine. It was found that methotrexate and vincristine did not affect TGF- b1 production, while doxorubicine used at a dose of 1β100 ug/ml, significantly induced TGF- b1 production in both cell lines. p53 expression in T47D cells was higher than in MCF-7 cells where only doxorubicin induced strongly p53 expression. It should be noted, that Bcl-2 was better expressed in MCF-7 cells, while it was almost undetectable in T47D cells. Conclusion: In cells of human mammary carcinoma of MCF-7 and T47D lines doxorubicine, unlike vincristine and methotrexate, in dose depending manner induces production of TGF- b1. TGF- b1 production in carcinoma cells was associated with doxorubicine-mediated p53 expression in MCF-7 cells or high basal level of p53 in T47D cells. The cells of MCF-7 line were more sensitive to growth inhibition by exogenous TGF- b1 and to cisplatine action than T47D cells, but there was no difference between these cell lines in sensitivity to other anticancer drugs.Π¦Π΅Π»Ρ: ΠΏΡΠΎΠ²Π΅ΡΡΠΈ ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΠΈ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠ°, ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½Π°, Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Π° ΠΈ Π²ΠΈΠ½ΠΊΡΠΈΡΡΠΈΠ½Π° ΠΈΠ½Π΄ΡΡΠΈΡΠΎΠ²Π°ΡΡ
ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠΈΡΡΡΡΠ΅Π³ΠΎ ΡΠ°ΠΊΡΠΎΡΠ° ΡΠΎΡΡΠ° (TΠ€Π )-Ξ²1
ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° (Π»ΠΈΠ½ΠΈΠΈ MCF-7 ΠΈ T47D),
Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΡ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡ ΡΡΠΈΡ
ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊ TΠ€Π -Ξ²1
ΠΈ ΡΠΊΠ°Π·Π°Π½Π½ΡΠΌ ΠΏΡΠΎΡΠΈΠ²ΠΎΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΡΠΌ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°ΠΌ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ
ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Π΄Π»Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΡ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΡ TΠ€Π -Ξ²1
Π² ΠΊΠΎΠ½Π΄ΠΈΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΡΡΠ΅Π΄Π΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠΌΠ΅Π½ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ·.
Π£ΡΠΎΠ²Π΅Π½Ρ Π±Π΅Π»ΠΊΠΎΠ² p53 ΠΈ Bcl-2 ΠΎΡΠ΅Π½ΠΈΠ²Π°Π»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠ±Π»ΠΎΡΡΠΈΠ½Π³Π°. Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΊΠ»Π΅ΡΠΊΠΈ t47d, ΠΊΠΎΡΠΎΡΡΠ΅ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π»ΠΈΡΡ
Π±ΠΎΠ»ΡΡΠ΅ΠΉ ΡΠ΅Π·ΠΈΡΡΠ΅Π½ΡΠ½ΠΎΡΡΡΡ ΠΊ ΡΠΎΡΡΠΈΠ½Π³ΠΈΠ±ΠΈΡΡΡΡΠ΅ΠΌΡ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ TΠ€Π -Ξ²1
ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ MCF-7, ΠΎΠΊΠ°Π·Π°Π»ΠΈΡΡ ΠΌΠ΅Π½Π΅Π΅
ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΠΊ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½Ρ. ΠΠ΅ Π²ΡΡΠ²Π»Π΅Π½ΠΎ ΡΠ°Π·Π»ΠΈΡΠΈΠΉ ΠΌΠ΅ΠΆΠ΄Ρ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ MCF-7 ΠΈ T47D ΠΊ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ
ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠ° ΠΈΠ»ΠΈ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Π°, Ρ
ΠΎΡΡ ΠΊΠ»Π΅ΡΠΊΠΈ T47D Π±ΡΠ»ΠΈ Π±ΠΎΠ»Π΅Π΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΠΊ Π²ΠΈΠ½ΠΊΡΠΈΡΡΠΈΠ½Ρ. ΠΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°Ρ ΠΈ Π²ΠΈΠ½ΠΊΡΠΈΡΡΠΈΠ½
Π½Π΅ Π²Π»ΠΈΡΠ»ΠΈ Π½Π° ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ TΠ€Π -Ξ²1
ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ MCF-7 ΠΈ T47D, ΡΠΎΠ³Π΄Π° ΠΊΠ°ΠΊ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½ Π² Π΄ΠΎΠ·Π΅ 1β100 ΠΌΠΊΠ³/ΠΌΠ» ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΡΠΈΠ»ΠΈΠ²Π°Π»
ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ TΠ€Π -Ξ²1
. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ Π±Π΅Π»ΠΊΠ° p53 Π±ΡΠ»Π° Π±ΠΎΠ»Π΅Π΅ ΠΈΠ½ΡΠ΅Π½ΡΠΈΠ²Π½ΠΎΠΉ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
T47D, ΠΏΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ Ρ ΠΊΠ»Π΅ΡΠΊΠ°ΠΌΠΈ Π»ΠΈΠ½ΠΈΠΈ MCF-7,
ΠΈ Π»ΠΈΡΡ Π² ΡΠ»ΡΡΠ°Π΅ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½Π° Π½Π° ΠΊΠ»Π΅ΡΠΊΠΈ Π»ΠΈΠ½ΠΈΠΈ MCF-7 Π±ΡΠ»ΠΎ Π²ΡΡΠ²Π»Π΅Π½ΠΎ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ Π΅Π³ΠΎ ΡΡΠΎΠ²Π½Ρ. ΠΡΠΈ
ΡΡΠΎΠΌ Π±Π΅Π»ΠΎΠΊ Bcl-2 Π±ΡΠ» Π²ΡΡΠ²Π»Π΅Π½ ΡΠΎΠ»ΡΠΊΠΎ Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
MCF-7. ΠΡΠ²ΠΎΠ΄Ρ: Π² ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ
Π»ΠΈΠ½ΠΈΡΡ
ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
(MCF-7 ΠΈ T47D) Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½, Π² ΠΎΡΠ»ΠΈΡΠΈΠ΅ ΠΎΡ Π²ΠΈΠ½ΠΊΡΠΈΡΡΠΈΠ½Π° ΠΈ ΠΌΠ΅ΡΠΎΡΡΠ΅ΠΊΡΠ°ΡΠ°, Π΄ΠΎΠ·ΠΎΠ·Π°Π²ΠΈΡΠΈΠΌΠΎ ΠΈΠ½Π΄ΡΡΠΈΡΡΠ΅Ρ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΡ Π’Π€Π -Ξ²1
.
ΠΠ½Π΄ΡΠΊΡΠΈΡ Π΄ΠΎΠΊΡΠΎΡΡΠ±ΠΈΡΠΈΠ½ΠΎΠΌ Π’Π€Π -Ξ²1
Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π° Ρ ΠΈΠ½Π΄ΡΠΊΡΠΈΠ΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Ρ53 Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
MCF-7
ΠΈΠ»ΠΈ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ Π±Π°Π·Π°Π»ΡΠ½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΡΠΎΠ³ΠΎ Π±Π΅Π»ΠΊΠ° Π² ΠΊΠ»Π΅ΡΠΊΠ°Ρ
T47D. ΠΠ»Π΅ΡΠΊΠΈ Π»ΠΈΠ½ΠΈΠΈ MCF-7, Π±ΠΎΠ»Π΅Π΅ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ ΠΊ ΡΠΎΡΡΠΈΠ½Π³ΠΈΠ±ΠΈΡΡΡΡΠ΅ΠΌΡ
Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΠΊΠ·ΠΎΠ³Π΅Π½Π½ΠΎΠ³ΠΎ Π’Π€Π -Ξ²1
, ΡΠ΅ΠΌ ΠΊΠ»Π΅ΡΠΊΠΈ Π»ΠΈΠ½ΠΈΠΈ T47D, ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΈ Π±ΠΎΠ»Π΅Π΅ Π²ΡΡΠ°ΠΆΠ΅Π½Π½ΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ
ΠΊ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΡΠΈΡΠΏΠ»Π°ΡΠΈΠ½Π°, Π½ΠΎ Π½Π΅ ΠΎΡΠ»ΠΈΡΠ°ΡΡΡΡ ΠΏΠΎ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ ΠΎΡ Π΄ΡΡΠ³ΠΈΡ
ΡΠΈΡΠΎΡΡΠ°ΡΠΈΠΊΠΎΠ²